Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

NCT00729027 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1015

Enrollment

INDUSTRY

Sponsor class

Stopped AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy

Conditions

Hypercholesterolemia

Interventions

DRUG: 25 mg/day AVE5530
DRUG: 50 mg/day AVE5530
DRUG: placebo

Sponsor

Sanofi